Author:
Jang Sekwon,Poretta Tayla,Bhagnani Tarun,Harshaw Qing,Burke Matthew,Rao Sumati
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. US Cancer Statistics Working Group. US Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999–2016): US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. 2019.
https://gis.cdc.gov/Cancer/USCS/DataViz.html
. Accessed November 2019.
2. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cutaneous Melanoma Version 1.2020.
https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
. Accessed Jan 2020.
3. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.
4. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.
5. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献